Atlas Trials

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Clinical trial NCT01087294 · COMPLETED

Trial details

NCT number
NCT01087294
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Leukemia, B-cellLymphoma, HodgkinsLymphoma, Non-hodgkinsLymphoma, B-Cell
Start date
2010-08-04
Primary completion
2024-03-08
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.